Yale-New Haven Hospital
- Type
- Teaching hospital
- Where
- New Haven, CT
- Medicare CCN
- 070022
- Received
- $2,960,627 in 234 records, 2025 ($269,573 general, $2,691,054 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Nonprofit contractor: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Plan sponsor: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Federal award recipient: YALE NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Lobbying client: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying registrant: YALE-NEW HAVEN HOSPITAL Fuzzy (name and state)
- Nonprofit: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 61 | $269,573 |
| 2025 | Research payment | 173 | $2,691,054 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 173 | $2,691,054 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 23 | $127,380 |
| Grant | 9 | $49,879 |
| Long term medical supply or device loan | 4 | $37,241 |
| Space rental or facility fees (teaching hospital only) | 13 | $28,553 |
| Debt forgiveness | 6 | $18,744 |
| Education | 2 | $5,125 |
| Honoraria | 1 | $2,424 |
| Charitable Contribution | 3 | $225 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $120,313 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#A phase II study of NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell | 2025 |
| 2025-12-31 | Stryker Corporation | $2,133 | Long term medical supply or device loan | In-kind items and services | GYNNIE Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,864 | Long term medical supply or device loan | In-kind items and services | NA Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $398 | Research payment | In-kind items and services | Biograph mCT X-4R Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Software License Yale Myocardial Blood Flow Imaging | 2025 |
| 2025-12-31 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-22 | ABBVIE INC. | $203,470 | Research payment | In-kind items and services | ELAHERE Drug, ONCOLOGY | A phase II evaluation of the safety and efficacy of mirvetuximab soravtansine (IMGN853) in women with folate receptor po | 2025 |
| 2025-12-19 | Olympus America Inc. | $1,000 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-18 | Hologic Sales and Service, LLC | $15,063 | Long term medical supply or device loan | In-kind items and services | SECURVIEW DIAGNOSTIC WORKSTATION Device, Breast and Skeletal Health | 2025 | |
| 2025-12-17 | Alnylam Pharmaceuticals Inc. | $95 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-17 | Alnylam Pharmaceuticals Inc. | $25 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-12-15 | Regeneron Pharmaceuticals, Inc. | $100 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-12-12 | Shockwave Medical, Inc | $1,910 | Research payment | Cash or cash equivalent | Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | 2025 | |
| 2025-12-12 | Novartis Pharmaceuticals Corporation | $780 | Research payment | Cash or cash equivalent | KISQALI Drug, Oncology | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | 2025 |
| 2025-12-05 | Verastem, Inc. | $7,002 | Research payment | Cash or cash equivalent | VSTM-100489 | 2025 | |
| 2025-12-05 | Shockwave Medical, Inc | $3,461 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-12-04 | Abbott Laboratories | $50 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-03 | Karyopharm Therapeutics Inc. | $6,701 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $4,236 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $2,399 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $972 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $716 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | $254 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-27 | Becton, Dickinson and Company | $100 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-11-25 | Abbott Laboratories | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-11-20 | ABBVIE INC. | $203,470 | Research payment | In-kind items and services | ELAHERE Drug, ONCOLOGY | A phase II evaluation of the safety and efficacy of mirvetuximab soravtansine (IMGN853) in women with folate receptor po | 2025 |
| 2025-11-20 | Boston Scientific Corporation | $105,000 | Research payment | Cash or cash equivalent | FARAPULSE Device, FARAPULSE_RM | Concomitant Atrial Fibrillation Ablation and Left Atrial Appendage Occlusion in Real-World Practice | 2025 |
| 2025-11-20 | Abbott Laboratories | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FREESTYLE LIBRE 3 Device, Diabetes Care | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $95 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-19 | Alnylam Pharmaceuticals Inc. | $25 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-11-12 | Verastem, Inc. | $16,010 | Research payment | Cash or cash equivalent | VSTM-100489 | 2025 | |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $17,716 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $4,236 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $2,399 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $1,625 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $716 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-05 | Karyopharm Therapeutics Inc. | $228 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-04 | Abbott Laboratories | $50 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-11-04 | Abbott Laboratories | $50 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-10-30 | PFIZER INC. | $2,584 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-28 | Alnylam Pharmaceuticals Inc. | $48 | Research payment | In-kind items and services | A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) | 2025 | |
| 2025-10-27 | Olympus America Inc. | $6,000 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-10-27 | Medical Device Business Services, Inc. | $2,260 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-10-27 | E.R. Squibb & Sons, L.L.C. | $1,449 | Research payment | Cash or cash equivalent | Phase III OLE of KarXT in Acute Bipolar_BALSAM3 | 2025 | |
| 2025-10-27 | Olympus America Inc. | $1,000 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-10-22 | Alexion Pharmaceuticals, Inc. | $113 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-20 | Shockwave Medical, Inc | $1,910 | Research payment | Cash or cash equivalent | Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | 2025 | |
| 2025-10-17 | National Marrow Donor Program | $17,160 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-16 | Boston Scientific Corporation | $305,000 | Research payment | Cash or cash equivalent | FARAPULSE Device, FARAPULSE_RM | Concomitant Atrial Fibrillation Ablation and Left Atrial Appendage Occlusion in Real-World Practice | 2025 |
| 2025-10-13 | ABBVIE INC. | $203,470 | Research payment | In-kind items and services | ELAHERE Drug, ONCOLOGY | A phase II evaluation of the safety and efficacy of mirvetuximab soravtansine (IMGN853) in women with folate receptor po | 2025 |
| 2025-10-10 | National Marrow Donor Program | $2,325 | Research payment | Cash or cash equivalent | 1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy fo | 2025 | |
| 2025-10-09 | Novartis Pharmaceuticals Corporation | $141,482 | Research payment | In-kind items and services | KISQALI Drug, Oncology | A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patients Selection for Moderate to Hig | 2025 |
| 2025-10-08 | Novartis Pharmaceuticals Corporation | $394 | Research payment | In-kind items and services | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an | 2025 | |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $2,856 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $2,673 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $2,399 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $2,017 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $2,017 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $750 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $750 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-09-17 | SERVIER PHARMACEUTICALS LLC | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-12 | Shockwave Medical, Inc | $2,884 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-09-12 | Shockwave Medical, Inc | $2,140 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-09-08 | Abbott Laboratories | $139 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-08 | Abbott Laboratories | $50 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-09-04 | Siemens Medical Solutions USA, Inc. | $11,756 | Grant | In-kind items and services | 2025 | ||
| 2025-09-04 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-09-04 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-27 | GE HEALTHCARE | $1,500 | Research payment | Cash or cash equivalent | Point of Care Lung Ultrasound Examination in Patients with Shortness of Breath | 2025 | |
| 2025-08-04 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-01 | PFIZER INC. | $51,453 | Research payment | Cash or cash equivalent | PRE CLINICAL | 2025 | |
| 2025-07-23 | ARGENX US, INC. | $49,532 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-07-23 | ARGENX US, INC. | $39,707 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-07-23 | National Marrow Donor Program | $17,435 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-17 | Stryker Corporation | $1,800 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS II STUDY | 2025 |
| 2025-07-17 | TransMedics, Inc. | $1,200 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-OHP-II | 2025 |
| 2025-07-10 | HISTOSONICS, INC. | $12,845 | Research payment | Cash or cash equivalent | The HistoSonics Edison System for treatment of primary solid renal tumors using histotripsy | 2025 | |
| 2025-07-09 | Stryker Corporation | $5,063 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | REVCORE FOR IN STENT THROMBOSIS (REVIT) | 2025 |
| 2025-07-09 | Stryker Corporation | $5,063 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-07-08 | Luminex Corporation | $2,424 | Honoraria | In-kind items and services | LIAISON PLEX Device, Device | 2025 | |
| 2025-07-03 | Karyopharm Therapeutics Inc. | $6,030 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | $4,236 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | $2,073 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | $198 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | $99 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | $65 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-01 | PFIZER INC. | $27,215 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED OPENLABEL 3PERIOD CROSSOVER SINGLEDOSE 2PART STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE EFFEC | 2025 | |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,929 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,550 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS II STUDY | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $1,350 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $955 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $859 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PROTRIEVE PROTECTOR STUDY (PROTECTOR) | 2025 |
| 2025-06-30 | Stryker Corporation | $826 | Research payment | Cash or cash equivalent | FLOWTRIEVER CATHETER, S Device, VTE | THE PEERLESS II STUDY | 2025 |
| 2025-06-27 | E.R. Squibb & Sons, L.L.C. | $79,067 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibro | 2025 | |
| 2025-06-26 | Novartis Pharmaceuticals Corporation | $106,112 | Research payment | In-kind items and services | KISQALI Drug, Oncology | A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patients Selection for Moderate to Hig | 2025 |
| 2025-06-25 | Eisai Inc. | $125 | Education | Cash or cash equivalent | 2025 | ||
| 2025-06-18 | GE HEALTHCARE | $41,440 | Research payment | Cash or cash equivalent | Point of Care Lung Ultrasound Examination in Patients with Shortness of Breath | 2025 | |
| 2025-06-11 | Alexion Pharmaceuticals, Inc. | $109 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-11 | Abbott Laboratories | $45 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-06-10 | Incyte Corporation | $5,000 | Education | Cash or cash equivalent | 2025 | ||
| 2025-06-03 | Siemens Medical Solutions USA, Inc. | $189,280 | Research payment | In-kind items and services | Biograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Personalized task-based respiratory motion correction for low-dose PET-CT | 2025 |
| 2025-06-02 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-06-02 | Karyopharm Therapeutics Inc. | $750 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-06-02 | Karyopharm Therapeutics Inc. | $750 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-06-02 | Karyopharm Therapeutics Inc. | $750 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-06-02 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-30 | Shockwave Medical, Inc | $1,730 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-05-30 | Shockwave Medical, Inc | $500 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-05-29 | Siemens Medical Solutions USA, Inc. | $5,400 | Grant | In-kind items and services | Automated Blood Coagulation Analyzer CS-2500 Device, DX - Diagnostics incl. all products and services | 2025 | |
| 2025-05-27 | Alexion Pharmaceuticals, Inc. | $333 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-23 | Incyte Corporation | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MONJUVI Drug, Oncology | 2025 | |
| 2025-05-22 | Genentech USA, Inc. | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Phesgo Biological, BioOncology | 2025 | |
| 2025-05-21 | PFIZER INC. | $20,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-21 | ARRAY BIOPHARMA INC | $10,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-21 | PFIZER INC. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-21 | PFIZER INC. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-21 | PFIZER INC. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-21 | PFIZER INC. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-20 | Ambu Inc. | $3,095 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-05-14 | Alexion Pharmaceuticals, Inc. | $379 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-08 | ABBVIE INC. | $135,647 | Research payment | In-kind items and services | ELAHERE Drug, ONCOLOGY | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FR)-positi | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $4,236 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $3,421 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $2,856 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $473 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-05 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-05-02 | Siemens Medical Solutions USA, Inc. | $504 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-05-01 | Alexion Pharmaceuticals, Inc. | $821 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-01 | Alexion Pharmaceuticals, Inc. | $745 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-01 | Alexion Pharmaceuticals, Inc. | $303 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-01 | Alexion Pharmaceuticals, Inc. | $111 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-01 | Alexion Pharmaceuticals, Inc. | $70 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-29 | Alexion Pharmaceuticals, Inc. | $25 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-04-28 | KLS-Martin L.P. | $8,264 | Debt forgiveness | Cash or cash equivalent | IPS, IMPLANT, CRANIAL, 00089, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-04-28 | KLS-Martin L.P. | $1,975 | Debt forgiveness | Cash or cash equivalent | IPS, SUPPLEMENTAL MODEL, FULL, 00007, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-04-25 | National Marrow Donor Program | $17,265 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-22 | Medical Device Business Services, Inc. | $2,260 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-04-16 | Novartis Pharmaceuticals Corporation | $7,940 | Research payment | Cash or cash equivalent | KISQALI Drug, Oncology | Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence | 2025 |
| 2025-04-14 | BioXcel Therapeutics, Inc. | $14,621 | Research payment | Cash or cash equivalent | BXCL-701-201 | 2025 | |
| 2025-04-09 | Abbott Laboratories | $124 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-04-09 | Abbott Laboratories | $45 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-04-07 | Karyopharm Therapeutics Inc. | $4,236 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-04-07 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-04-07 | Shockwave Medical, Inc | $1,500 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-04-07 | Karyopharm Therapeutics Inc. | $400 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-04-04 | TransMedics, Inc. | $18,689 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-OHP-II | 2025 |
| 2025-04-02 | Alexion Pharmaceuticals, Inc. | $140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-03-19 | PFIZER INC. | $17,033 | Research payment | Cash or cash equivalent | PRE CLINICAL | 2025 | |
| 2025-03-12 | Eisai Inc. | $5,000 | Grant | Cash or cash equivalent | Lenvima Drug, Oncology | 2025 | |
| 2025-03-11 | Zimmer Biomet Holdings, Inc. | $108 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-03-07 | Shockwave Medical, Inc | $2,030 | Research payment | Cash or cash equivalent | Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease | 2025 | |
| 2025-03-06 | Karyopharm Therapeutics Inc. | $17,716 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-03-06 | Karyopharm Therapeutics Inc. | $6,701 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-03-06 | Karyopharm Therapeutics Inc. | $2,017 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-03-06 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-03-06 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-03-06 | Karyopharm Therapeutics Inc. | $1,788 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
The latest 200 records of 234.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) New Haven, CT | County South Central Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 134,349 | 570,598 | 3,624,508 |
| Population, 2020 census P1 | 134,023 | - | 3,605,944 |
| Median age B01002 | 31.9 | 40.2 | 41.1 |
| Under 18 B01001 | 21.3% | 19.6% | 20.2% |
| 65 and over B01001 | 11.8% | 18.6% | 18.5% |
| Households B11001 | 54,773 | 230,673 | 1,434,007 |
| Foreign born B05002 | 18.0% | 13.7% | 15.7% |
| Median household income B19013 | $56,851 | $88,197 | $95,781 |
| Median family income B19113 | $68,668 | $115,384 | $122,706 |
| Per capita income B19301 | $36,242 | $49,766 | $55,915 |
| Poverty rate B17001 | 23.9% | 11.4% | 10.0% |
| Unemployment rate B23025 | 8.4% | 6.0% | 5.6% |
| Civilian labor force B23025 | 69,528 | 307,607 | 1,959,490 |
| Mean commute (minutes) B08013 | 21.5 | 23.5 | 26.5 |
| Bachelor's degree or higher B15003 | 38.9% | 42.0% | 42.5% |
| Housing units B25001 | 60,333 | 248,267 | 1,541,822 |
| Owner-occupied B25003 | 28.4% | 60.5% | 66.5% |
| Renters B25003 | 71.6% | 39.5% | 33.5% |
| Median home value B25077 | $287,100 | $353,100 | $366,900 |
| Median gross rent B25064 | $1,488 | $1,525 | $1,488 |
| White, not Hispanic B03002 | 30.0% | 58.5% | 61.9% |
| Black B03002 | 27.6% | 13.0% | 9.8% |
| Hispanic or Latino B03002 | 31.0% | 19.5% | 18.3% |
| Asian B03002 | 5.2% | 4.5% | 4.7% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.
Comments